• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Neurological

These tiny fibers may prove better at delivering drugs to the brain

June 5, 2020 By Chris Newmarker

tiny fibers PLGA brain Martin Luther University Halle-Wittenberg drug delivery brain

German researchers have developed mats made of biodegradable fibers only a few microns thick that could prove advantageous to deliver certain drugs to the brain. The drug nimodipine, for example, could prevent nerve cells from dying after brain surgery. Health providers already use it to treat cerebral hemorrhages, but it degrades very quickly and has […]

Filed Under: Featured, Materials Testing, Neurological, Research & Development Tagged With: Martin Luther University Halle-Wittenberg, University Hospital Halle

AxoSim touts results of nerve-on-a-chip study

July 9, 2019 By Nancy Crotti

AxoSim

A new study of AxoSim’s Nerve-on-a-Chip technology shows that the platform accurately provides key physiological readouts that could help speed the development of drugs to treat neurological disorders. The study also shows that Nerve-on-a-Chip technology is the first all-human in vitro model that can measure critical factors that were formerly only available using live animal models. […]

Filed Under: Featured, Neurological, Research & Development, Stem Cells Tagged With: AxoSim

Kurve, Suerat partnered in nasal-delivery migraine treatment deal

July 8, 2019 By Danielle Kirsh

kurve-technology-logo

Kurve Technology last week announced a new development and collaboration agreement with Seurat Therapeutics for migraine prevention in adults. Mill Creek, Wash.-based Kurve Technology develops and markets intranasal drug delivery devices that transport liquid compounds from the nose to the brain to treat Alzheimer’s PTSD, multiple sclerosis and more. “Both Seurat and Kurve are proud […]

Filed Under: Drug-Device Combinations, Neurological Tagged With: Kurve Technology, Seurat Therapeutics

Kurve Technology wins DoD contract for drug delivery tech

May 31, 2019 By Danielle Kirsh

kurve-technology

Kurve Technology won a U.S. Defense Dept. contract to test a new formulation for combating traumatic brain injuries. The Mill Creek, Wash.-based company makes a controlled particle dispersion device designed to deliver liquid drugs through a controlled, turbulent flow, according to the company’s website. Its ViaNase electronic atomizer can deliver most drug compounds through the […]

Filed Under: Drug-Device Combinations, Neurological Tagged With: Kurve Technology

Teva wins EU nod for Ajovy migraine prophylactic

April 2, 2019 By Fink Densford

Teva Pharmaceutical logo - updated

Teva (NYSE:TEVA) said yesterday that it won EC Marketing Authorization in the European Union for its Ajovy pre-filled syringe injection meant to serve as a prophylaxis for migraines in adults who experience at least four migraine days per month. The Israel-based company said that Ajovy is a humanized monoclonal antibody that binds to the calcitonin gene-related […]

Filed Under: Featured, Neurological, Pharmaceuticals, Regulatory/Compliance Tagged With: Teva

Sage wins historic FDA nod for postpartum depression therapy

March 20, 2019 By Sarah Faulkner

Sage Therapeutics

Sage Therapeutics (NSDQ:SAGE) this week won FDA approval for the first medicine indicated to treat postpartum depression. The Cambridge, Mass.-based company’s injection therapy, Zulresso, is slated to be available in late June. Postpartum depression is the most common medical complication of childbirth, according to Sage, and affects roughly one in nine women who have given birth […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Neurological, Wall Street Beat Tagged With: sagetherapeutics

Aptar Pharma touts FDA approval of nasal spray device

March 19, 2019 By Sarah Faulkner

Aptar Pharma nasal spray device

Aptar Pharma said this week that its Bidose nasal spray device won FDA approval for use with a breakthrough depression therapy. The Crystal Lake, Ill.-based company’s Bidose tech enables two-shot nasal drug delivery. Aptar touted its manufacturing facility in Congers, NY, which supports the manufacture of nasal and injectable drug delivery systems. “We are pleased […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Neurological, Pharmaceuticals Tagged With: aptarpharma

Alcyone wins breakthrough device status for delivery device

March 11, 2019 By Sarah Faulkner

Alcyone Lifesciences logo

Alcyone Lifesciences said today that its ThecaFlex DRx system won breakthrough device status from the FDA. The Lowell, Mass.-based company’s system features an implantable subcutaneous port and intrathecal catheter used to provide access for cerebrospinal fluid aspiration and infusion of therapies. “The breakthrough device designation for the ThecaFlex DRx System is an important milestone in […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Neurological, Pharmaceuticals, Regulatory/Compliance Tagged With: Alcyone Lifesciences

FDA approves J&J’s nasal spray for treatment-resistant depression

March 6, 2019 By Sarah Faulkner

Johnson & Johnson

The FDA has approved Johnson & Johnson‘s (NYSE:JNJ) esketamine nasal spray for people living with treatment-resistant depression. The company’s product, Spravato, is an intranasal formulation of ketamine – a horse tranquilizer that is also known as Special K. The drug won support for approval from an FDA advisory committee earlier this year. Spravato is the […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Neurological, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: janssen, Johnson & Johnson

FDA committee backs J&J’s nasal spray for depression

February 13, 2019 By Sarah Faulkner

Updated Janssen logo

An FDA advisory committee has voted to support Johnson & Johnson‘s (NYSE:JNJ) Spravato esketamine nasal spray product as a therapy for adults living with treatment-resistant depression. J&J’s Janssen touted that if the U.S. regulatory agency decides to approve Spravato, it would be the first medicine in 30 years to sport a new mechanism of action […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Neurological, Pharmaceuticals, Wall Street Beat Tagged With: janssen, Johnson & Johnson

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 15
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS